To better study the influence of degree and pattern of HRs expression on clinical behavior and trastuzumab efficacy, we recruited 872 patients with TP breast cancer selected on the basis of a HER2-positive status and simultaneous expression of both ER and PgR in at least 1% of the tumor cells. This evidence concerns the gene PGR and breast cancer.